Clinical Trials · NCT03136484
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 788
- Start date
- Mar 2017
- Locations
- 119 sites, 12 countries
- Primary endpoint
- Change in HbA1c